Xiamen Kingdomway Group Company (002626.SZ) Bundle
Curious whether Xiamen Kingdomway Group (002626.SZ) is a buy, hold or watch? Dive into a data-driven snapshot: in H1 2025 the company posted operating revenue of ¥1.728 billion (+13.46% YoY) with its nutrition and health segment contributing ¥1.703 billion (reported as 9% of total revenue), while Q1 2025 revenue was ¥827 million with net income of ¥122 million; on a trailing twelve‑month basis to 30 Sep 2025 revenue reached ¥3.50 billion and net income was ¥482.09 million (EPS ¥0.79, EBITDA ¥775.03 million). Balance‑sheet and liquidity markers show total assets of ¥8.38 billion, liabilities of ¥3.80 billion, equity of ¥4.58 billion, a debt‑to‑equity ratio of 0.66, cash and short‑term investments of ¥3.14 billion and a net cash position of ¥100.14 million, supported by a current ratio of 2.64 and quick ratio of 2.09; operating cash flow TTM was ¥521 million versus capex of ¥365 million. Market and valuation metrics include an enterprise value of ¥11.29 billion, market cap of ¥11.34 billion (26 Nov 2025), TTM P/E of 23.52, forward P/E 25.48, P/B 2.47, P/S 3.24, EV/EBITDA 13.82 and EV/FCF 25.27. Analysts forecast revenue rising to ¥3.852 billion in 2025, ¥4.49 billion in 2026 and ¥5.103 billion in 2027, while profitability improved sharply (H1 2025 parent net profit ¥247 million, +90.12% YoY, net margin 14.28% vs 7.51% prior); key risks and catalysts covered include raw material price volatility (e.g., Vitamin A), intense sector competition, regulatory and environmental/production safety exposures, FX risk, planned CoQ10 capacity expansion, e‑commerce push, a planned $17.2 million U.S. acquisition and strategic use of synthetic biology and international brands-read on for the full breakdown and what these figures mean for investors
Xiamen Kingdomway Group Company (002626.SZ) - Revenue Analysis
Key revenue milestones and trends for Xiamen Kingdomway Group Company (002626.SZ) show steady growth through 2024-2025 and positive analyst projections for 2026-2027.
- H1 2025 operating revenue: 1.728 billion yuan - a year-on-year increase of 13.46%.
- Core nutrition & health products revenue (H1 2025): 1.703 billion yuan, reported as 9% of total revenue.
- Q1 2025 revenue: 827 million yuan; Q1 2025 net income: 122 million yuan.
- Full-year 2024 revenue: 3.24 billion yuan - up 4.43% versus 2023.
- TTM revenue as of 30 Sep 2025: 3.50 billion yuan - a 12.06% year-on-year rise.
| Period | Revenue (billion CNY) | Year-on-Year Change | Notes |
|---|---|---|---|
| Q1 2025 | 0.827 | - | Net income: 0.122 billion CNY |
| H1 2025 | 1.728 | +13.46% | Nutrition & health products: 1.703 billion CNY (reported as 9% of total) |
| Full-year 2024 | 3.240 | +4.43% | Annual reported revenue |
| TTM (to 30 Sep 2025) | 3.500 | +12.06% | Trailing twelve months revenue |
| Analyst projection 2025 | 3.852 | Projected | Consensus estimate |
| Analyst projection 2026 | 4.490 | Projected | Consensus estimate |
| Analyst projection 2027 | 5.103 | Projected | Consensus estimate |
- Trajectory: H1 2025 growth (13.46% YoY) and TTM improvement (12.06% YoY) underpin analyst forecasts of continued revenue expansion to 5.103 billion CNY by 2027.
- Profitability indicator: Q1 2025 net income of 122 million CNY alongside growing revenues suggests margin recovery or operational leverage in early 2025.
- Concentration note: the disclosed 1.703 billion CNY from nutrition & health products warrants scrutiny given its reported 9% share of total revenue.
Further context on the company's history, ownership and business model: Xiamen Kingdomway Group Company: History, Ownership, Mission, How It Works & Makes Money
Xiamen Kingdomway Group Company (002626.SZ) - Profitability Metrics
Key profitability indicators for Xiamen Kingdomway Group Company (002626.SZ) show marked improvement through 2024 and into the first three quarters of 2025, driven by stronger gross performance and improved margins.
- Net profit attributable to parent (1H 2025): 247.00 million yuan - up 90.12% year-on-year.
- Net profit margin (1H 2025): 14.28% (vs. 7.51% in 1H 2024).
- Net income (full year 2024): 342.00 million yuan - up 23.59% year-on-year.
- TTM net income (as of 2025-09-30): 482.09 million yuan.
- TTM EPS (as of 2025-09-30): 0.79 yuan per share.
- TTM EBITDA (as of 2025-09-30): 775.03 million yuan.
| Metric | Period | Value (yuan) | Change / Notes |
|---|---|---|---|
| Net profit attributable to parent | 1H 2025 | 247,000,000 | +90.12% YoY |
| Net profit margin | 1H 2025 | 14.28% | Up from 7.51% in 1H 2024 |
| Net income | FY 2024 | 342,000,000 | +23.59% YoY |
| TTM net income | As of 2025-09-30 | 482,090,000 | Trailing twelve months |
| TTM EPS | As of 2025-09-30 | 0.79 | Yuan per share (TTM) |
| TTM EBITDA | As of 2025-09-30 | 775,030,000 | Adjusted operating performance |
For broader context on the company's background and how it generates revenue, see: Xiamen Kingdomway Group Company: History, Ownership, Mission, How It Works & Makes Money
Xiamen Kingdomway Group Company (002626.SZ) - Debt vs. Equity Structure
Xiamen Kingdomway Group Company (002626.SZ) shows a capital structure that leans toward equity financing with moderate leverage as of the September 30, 2025 reporting date. Key balance-sheet figures indicate substantial asset backing and a comfortable short-term liquidity position.- Total assets: ¥8.38 billion (as of Sep 30, 2025)
- Total liabilities: ¥3.80 billion (as of Sep 30, 2025)
- Total equity: ¥4.58 billion (as of Sep 30, 2025)
- Debt-to-equity ratio: 0.66 (as of Sep 30, 2025)
- Current ratio: 2.64 (as of Sep 30, 2025)
- Enterprise value (EV): ¥11.29 billion
- Market capitalization: ¥11.34 billion (as of Nov 26, 2025)
| Metric | Amount (¥) | Date | Implication |
|---|---|---|---|
| Total Assets | 8,380,000,000 | Sep 30, 2025 | Solid asset base to support operations and creditors |
| Total Liabilities | 3,800,000,000 | Sep 30, 2025 | Moderate absolute debt level |
| Total Equity | 4,580,000,000 | Sep 30, 2025 | Equity-funded majority of the balance sheet |
| Debt-to-Equity Ratio | 0.66 | Sep 30, 2025 | Moderate leverage - less than 1.0 |
| Current Ratio | 2.64 | Sep 30, 2025 | Strong short-term liquidity |
| Enterprise Value (EV) | 11,290,000,000 | - | Overall valuation including debt and cash |
| Market Capitalization | 11,340,000,000 | Nov 26, 2025 | Equity market value close to EV (low net debt or balanced adjustments) |
- The debt-to-equity ratio of 0.66 indicates the company uses debt conservatively; equity covers a larger share of the capital structure.
- A current ratio of 2.64 suggests the company can easily meet short-term obligations without resorting to new borrowing.
- The near parity of EV (¥11.29B) and market cap (¥11.34B) implies net debt is small or offset by cash equivalents in the balance sheet.
- Investors should monitor future changes in liabilities and earnings volatility, as moderate leverage can amplify returns but also downside risk.
Xiamen Kingdomway Group Company (002626.SZ) - Liquidity and Solvency
Assessing liquidity and solvency for Xiamen Kingdomway Group Company (002626.SZ) as of September 30, 2025 highlights a structurally liquid balance sheet, solid cash generation and manageable investment needs.
- Cash & short-term investments: ¥3.14 billion (as of 2025-09-30)
- Net cash position: ¥100.14 million (as of 2025-09-30)
- Quick ratio: 2.09 (as of 2025-09-30)
- Interest coverage ratio: 14.23 (as of 2025-09-30)
- Operating cash flow (TTM to 2025-09-30): ¥521 million
- Capital expenditures (TTM to 2025-09-30): ¥365 million
| Metric | Value | Context / Implication |
|---|---|---|
| Cash & short-term investments | ¥3,140,000,000 | High immediate liquidity buffer |
| Net cash position | ¥100,140,000 | Assets exceed interest-bearing liabilities by a small margin |
| Quick ratio | 2.09 | More than twice current liabilities covered by liquid assets |
| Interest coverage ratio | 14.23 | Operating income covers interest expense comfortably |
| Operating cash flow (TTM) | ¥521,000,000 | Positive cash generation from operations |
| Capital expenditures (TTM) | ¥365,000,000 | Investment level supported by operating cash flow |
Key liquidity dynamics show that operating cash flow (¥521m) exceeds capital expenditures (¥365m), supporting reinvestment and debt service. The strong quick ratio (2.09) and high interest coverage (14.23) indicate low short-term solvency risk, while a modest net cash position (¥100.14m) reflects leverage management relative to cash reserves. For broader corporate context and strategic background, see Xiamen Kingdomway Group Company: History, Ownership, Mission, How It Works & Makes Money
Xiamen Kingdomway Group Company (002626.SZ) - Valuation Analysis
Xiamen Kingdomway Group Company (002626.SZ) displays valuation metrics that position it in the mid-to-high valuation band among peers in the Chinese pharmaceutical/healthcare sector as of November 26, 2025. Key market multiples reflect investor expectations about near-term earnings growth, balance-sheet strength and cash-generation capacity.- Trailing twelve months (TTM) P/E: 23.52 - indicates current market pricing relative to last 12 months' reported earnings.
- Forward P/E (next fiscal year projection): 25.48 - market-implied earnings growth is moderate and priced conservatively relative to TTM.
- Price-to-Book (P/B): 2.47 - market values the company at roughly 2.5x its book equity, signaling a premium to net asset value.
- Price-to-Sales (P/S): 3.24 - investors pay about 3.24x annual revenue, relevant for revenue-growth comparisons among peers.
- EV/EBITDA: 13.82 - enterprise valuation implies a mid-cycle earnings multiple, useful for capital-structure neutral comparisons.
- EV/FCF: 25.27 - the firm is valued at over 25x free cash flow, highlighting the market's emphasis on cash-generation prospects.
| Metric | Value | Interpretation |
|---|---|---|
| TTM P/E | 23.52 | Moderate earnings multiple; suggests expected stability but limited near-term upside without growth acceleration |
| Forward P/E | 25.48 | Higher than TTM P/E - market expects either margin compression or slower earnings growth next fiscal year |
| P/B | 2.47 | Premium to book value; signals intangible value, brand, or higher ROE expectations |
| P/S | 3.24 | Reflects revenue valuation; useful when earnings are volatile |
| EV/EBITDA | 13.82 | Comparable across capital structures; indicates moderate operating valuation |
| EV/FCF | 25.27 | Relatively elevated; market prices future cash generation at a premium |
- Relative valuation implications: P/E and EV multiples place Kingdomway in a range where earnings stability and cash conversion matter most for re-rating.
- Balance-sheet lens: P/B ~2.47 implies investors expect returns on invested capital above cost of equity to justify the premium.
- Cash flow focus: EV/FCF of 25.27 requires consistent FCF delivery to sustain current valuation levels.
Xiamen Kingdomway Group Company (002626.SZ) - Risk Factors
Xiamen Kingdomway Group Company (002626.SZ) operates in nutrition, health products, and active pharmaceutical ingredients. Key risks stem from commodity exposure, competitive pressures, regulatory shifts, environmental and safety requirements, and international operations. Below are the principal risk vectors, quantified stress scenarios, and sensitivities to help investors assess potential financial impact.- Raw material price volatility (e.g., Vitamin A): a primary margin risk due to concentrated inputs and limited short‑term hedging for some specialty vitamins.
- Intense sector competition: domestic and international peers pressure pricing, channel access, and R&D effectiveness.
- Regulatory and technological change: evolving GMP, food‑supplement rules, and digital/biotech advances can require CAPEX and restructuring.
- Environmental protection and production safety: manufacturing plants face upgrade costs, remediation liabilities, and potential production stoppages.
- Domestic policy fluctuations: shifts in industry subsidies, inspection frequency, or classification of products can materially affect sales and margins.
- Foreign exchange exposure: export revenue and overseas procurement create FX risk against RMB movements.
| Risk Category | Typical Trigger | Probability (illustrative) | Estimated Financial Sensitivity | Potential Mitigation |
|---|---|---|---|---|
| Raw material price volatility | Sharp increase in Vitamin A or other API prices | Medium-High (30%-50% annual volatility observed historically in niche vitamin markets) | 10% input price rise → gross margin compression of ~3-5 percentage points; 20% rise → 6-10 pts | Longer procurement contracts, strategic inventories, selective pass‑through pricing |
| Competitive pressure | New low‑cost entrants, channel consolidation | High | Market share erosion scenario: 3-7% revenue decline over 1-2 years; EBITDA margin pressure of 2-6 pts | Product differentiation, R&D investment, channel diversification |
| Regulatory & technological change | Reclassification of products, tighter GMP/food safety rules | Medium | One‑time compliance costs: RMB 100-400 million; recurring higher OPEX 1-3% of revenue | Proactive compliance, tech upgrades, regulatory monitoring |
| Environmental & production safety | Inspection failures, accidents, stricter emissions limits | Medium | Shutdowns or remediation could cost RMB 50-300 million; lost output impacting quarterly revenues | Capex for cleaner tech, stronger EHS protocols, insurance |
| Domestic policy fluctuations | Subsidy removal, changed inspection frequency, price controls | Medium | Revenue volatility 5-10% under adverse policy shifts; compliance costs variable | Policy engagement, flexible production planning, diversified product mix |
| Foreign exchange exposure | RMB appreciation/depreciation vs. USD/EUR | High (market‑driven) | If exports = 25-40% of revenue, a 5% RMB move can change reported revenue/EBITDA by ~1-3% | Natural hedges, FX forwards, pricing in local currencies |
- Balance‑sheet sensitivity: with a moderate leverage profile (illustrative debt/equity ~0.5-0.8 in comparable peers), margin compression or one‑time regulatory costs can materially impact net income and cash flows, increasing reliance on working‑capital management.
- Working capital and inventory risk: inventory builds to smooth raw‑material cycles tie up cash-an environment with 10-20% higher raw material prices can push inventory value and DIO materially higher.
- Revenue concentration risk: reliance on a few flagship products or major clients amplifies downside if competition or regulation reduces demand by 5-10%.
Xiamen Kingdomway Group Company (002626.SZ) - Growth Opportunities
Xiamen Kingdomway is positioning for accelerated top-line expansion through capacity build-out, M&A, digital channels and new technology adoption. Key growth vectors and related metrics:- Coenzyme Q10 capacity expansion targeted to lift global market share in the specialty nutraceutical segment.
- Analysts' consolidated revenue projections: 3.852 billion yuan (2025), 4.490 billion yuan (2026), 5.103 billion yuan (2027), implying ~15.2% compound annual growth rate (2025-2027).
- Strategic push into e-commerce to deepen domestic penetration and capture higher-margin direct-to-consumer sales.
- Planned $17.2 million acquisition of a U.S. nutritional supplements company to accelerate international brand presence and distribution.
- Deployment of synthetic biology as a core R&D platform to reduce production costs, accelerate product innovation and improve yields of high-value ingredients.
- Portfolio diversification via international brands (Doctor's Best, Zipfizz) to broaden channel reach and reduce single-market concentration risk.
| Metric | 2025 (proj) | 2026 (proj) | 2027 (proj) |
|---|---|---|---|
| Revenue (CNY) | 3,852,000,000 | 4,490,000,000 | 5,103,000,000 |
| YoY growth | - | 16.6% | 13.7% |
| 3-year CAGR (2025-2027) | ≈15.2% | ||
| Planned acquisition | $17.2 million (U.S. nutritional supplements company) | ||
| Key brands added | Doctor's Best; Zipfizz | ||
- Revenue trajectory driven by capacity scaling (CoQ10), cross-border brand acquisitions and higher-margin e-commerce mix.
- Synthetic biology investments can compress unit costs and enable novel SKUs, supporting both margin expansion and faster new-product time-to-market.
- Successful integration of the $17.2M U.S. target and effective channel synergy with Doctor's Best/Zipfizz could materially increase overseas revenue share.
Xiamen Kingdomway Group Company (002626.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.